Total Valuation
Bukwang Pharmaceutical Co., Ltd. has a market cap or net worth of ₩361.61B. The enterprise value is ―.
Market Cap₩361.61B
Enterprise Value―
Share Statistics
Bukwang Pharmaceutical Co., Ltd. has 98,664,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding98,664,670
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bukwang Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 3.05%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)3.05%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee362.30M
Profits Per Employee22.67M
Employee Count554
Asset Turnover0.40
Inventory Turnover2.01
Valuation Ratios
The current PE Ratio of Bukwang Pharmaceutical Co., Ltd. is 63.7. Bukwang Pharmaceutical Co., Ltd.’s PEG ratio is -0.05.
PE Ratio63.7
PS Ratio1.86
PB Ratio1.09
Price to Fair Value1.09
Price to FCF33.49
Price to Operating Cash Flow32.80
PEG Ratio-0.05
Income Statement
In the last 12 months, Bukwang Pharmaceutical Co., Ltd. had revenue of 200.71B and earned 12.57B in profits. Earnings per share was 152.00.
Revenue200.71B
Gross Profit95.72B
Operating Income14.16B
Pretax Income6.39B
Net Income12.57B
EBITDA19.65B
Earnings Per Share (EPS)152.00
Cash Flow
In the last 12 months, operating cash flow was 11.48B and capital expenditures -8.51B, giving a free cash flow of 2.97B billion.
Operating Cash Flow11.48B
Free Cash Flow2.97B
Free Cash Flow per Share30.11
Dividends & Yields
Bukwang Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.10
52-Week Price Change19.52%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)406.37K
Important Dates
Bukwang Pharmaceutical Co., Ltd. upcoming earnings date is Oct 27, 2026, TBA (Confirmed).
Last Earnings DateJul 21, 2026
Next Earnings DateOct 27, 2026
Ex-Dividend Date―
Financial Position
Bukwang Pharmaceutical Co., Ltd. as a current ratio of 2.59, with Debt / Equity ratio of 24.18%
Current Ratio2.59
Quick Ratio2.15
Debt to Market Cap0.21
Net Debt to EBITDA2.09
Interest Coverage Ratio3.63
Taxes
In the past 12 months, Bukwang Pharmaceutical Co., Ltd. has paid -6.05B in taxes.
Income Tax-6.05B
Effective Tax Rate-0.95
Enterprise Valuation
Bukwang Pharmaceutical Co., Ltd. EV to EBITDA ratio is 21.10, with an EV/FCF ratio of 37.18.
EV to Sales2.07
EV to EBITDA21.10
EV to Free Cash Flow37.18
EV to Operating Cash Flow22.43
Balance Sheet
Bukwang Pharmaceutical Co., Ltd. has ₩209.42B in cash and marketable securities with ₩80.65B in debt, giving a net cash position of ₩128.77B billion.
Cash & Marketable Securities₩209.42B
Total Debt₩80.65B
Net Cash₩128.77B
Net Cash Per Share₩1.31K
Tangible Book Value Per Share₩3.40K
Margins
Gross margin is 33.98%, with operating margin of 7.05%, and net profit margin of 6.26%.
Gross Margin33.98%
Operating Margin7.05%
Pretax Margin3.18%
Net Profit Margin6.26%
EBITDA Margin9.79%
EBIT Margin7.05%
Analyst Forecast
The average price target for Bukwang Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast20.05%
EPS Growth Forecast-25.74%